ALPN vs. FPRX, XNCR, ZYME, HARP, MGNX, RPRX, BGNE, BMRN, VTRS, and UTHR
Should you be buying Alpine Immune Sciences stock or one of its competitors? The main competitors of Alpine Immune Sciences include Five Prime Therapeutics (FPRX), Xencor (XNCR), Zymeworks (ZYME), Harpoon Therapeutics (HARP), MacroGenics (MGNX), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), and United Therapeutics (UTHR).
Alpine Immune Sciences (NASDAQ:ALPN) and Five Prime Therapeutics (NASDAQ:FPRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking.
In the previous week, Alpine Immune Sciences had 3 more articles in the media than Five Prime Therapeutics. MarketBeat recorded 3 mentions for Alpine Immune Sciences and 0 mentions for Five Prime Therapeutics. Alpine Immune Sciences' average media sentiment score of 1.85 beat Five Prime Therapeutics' score of 0.00 indicating that Alpine Immune Sciences is being referred to more favorably in the media.
Alpine Immune Sciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500.
Alpine Immune Sciences has a net margin of -65.17% compared to Five Prime Therapeutics' net margin of -554.71%. Alpine Immune Sciences' return on equity of -14.86% beat Five Prime Therapeutics' return on equity.
Alpine Immune Sciences received 74 more outperform votes than Five Prime Therapeutics when rated by MarketBeat users. Likewise, 64.46% of users gave Alpine Immune Sciences an outperform vote while only 55.96% of users gave Five Prime Therapeutics an outperform vote.
75.2% of Alpine Immune Sciences shares are held by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are held by institutional investors. 42.3% of Alpine Immune Sciences shares are held by insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Alpine Immune Sciences presently has a consensus price target of $52.33, indicating a potential downside of 19.45%. Given Alpine Immune Sciences' higher probable upside, analysts clearly believe Alpine Immune Sciences is more favorable than Five Prime Therapeutics.
Alpine Immune Sciences has higher revenue and earnings than Five Prime Therapeutics. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Alpine Immune Sciences beats Five Prime Therapeutics on 14 of the 17 factors compared between the two stocks.
Get Alpine Immune Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpine Immune Sciences Competitors List
Related Companies and Tools
